Annovis Bio Inc. Secures 18-Month NYSE Compliance Extension
June 20th, 2025 1:27 PM
By: Newsworthy Staff
Annovis Bio Inc. has been granted an 18-month period by the NYSE to meet listing requirements, ensuring its continued trading and development of neurodegenerative disease therapies.
Annovis Bio Inc. (NYSE: ANVS), a clinical-stage company focused on neurodegenerative diseases such as Alzheimer’s and Parkinson’s, has successfully negotiated an 18-month compliance extension with the New York Stock Exchange. This extension, effective from March 26, 2025, allows the company additional time to meet the NYSE's minimum market capitalization and stockholders’ equity requirements. The company's ability to continue trading on the NYSE during this period is contingent upon meeting specific milestones and adhering to other listing standards. Importantly, this development does not affect Annovis Bio's operational activities or its obligations to the Securities and Exchange Commission.
The company's commitment to developing therapies that target multiple neurotoxic proteins aims to restore brain function and enhance patients' lives. For further details, visit https://ibn.fm/D9Yzt.
Source Statement
This news article relied primarily on a press release disributed by InvestorBrandNetwork (IBN). You can read the source press release here,
